CBD3063 is a selective peptidomimetic modulator targeting the interaction between the N-type voltage-gated calcium channel Cav2.2 and its cytosolic auxiliary subunit, collapsin response mediator protein 2 (CRMP2). By disrupting this interaction, CBD3063 reduces the surface trafficking and membrane expression of Cav2.2, leading to decreased calcium influx and attenuation of nociceptive signaling. In preclinical studies, CBD3063 effectively reversed neuropathic and inflammatory pain behaviors in rodent models without inducing sedation, motor impairment, or cognitive deficits. Notably, it preserved normal somatosensory function, distinguishing it from existing Cav2.2 blockers like gabapentin. Additionally, CBD3063 exhibited anxiolytic-like effects, suggesting partial penetration of the blood-brain barrier.
MedKoo Cat#: 127622
Name: CBD3063
CAS#: 1281060-70-5
Chemical Formula: C16H25N5O2
Exact Mass: 319.2008
Molecular Weight: 319.41
Elemental Analysis: C, 60.17; H, 7.89; N, 21.93; O, 10.02
July 7, 2025 - Product CBD3063 Patent licensing News: MedKoo is excited to announce the licensing of patents of the novel compound CBD3063 from New York University and UNIVERSITY OF PITTSBURGH. This groundbreaking product is safeguarded by patents including US Serial No. 18/758,804 (Filing Date Jun 28, 2024) - Selective Peptidomimetic Modulators Of Cav2.2 (N-type) Voltage-gate Calcium Channels And Uses Thereof
The following data is based on the product molecular weight 319.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
